Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.41
TBIO's Cash to Debt is ranked lower than
74% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. TBIO: 0.41 )
Ranked among companies with meaningful Cash to Debt only.
TBIO' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 3.16 Max: No Debt
Current: 0.41
Equity to Asset 0.28
TBIO's Equity to Asset is ranked lower than
84% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. TBIO: 0.28 )
Ranked among companies with meaningful Equity to Asset only.
TBIO' s Equity to Asset Range Over the Past 10 Years
Min: -0.46  Med: 0.69 Max: 0.95
Current: 0.28
-0.46
0.95
F-Score: 4
Z-Score: -11.59
M-Score: -4.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -58.63
TBIO's Operating margin (%) is ranked lower than
69% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. TBIO: -58.63 )
Ranked among companies with meaningful Operating margin (%) only.
TBIO' s Operating margin (%) Range Over the Past 10 Years
Min: -63.96  Med: -13.85 Max: -1.53
Current: -58.63
-63.96
-1.53
Net-margin (%) -58.81
TBIO's Net-margin (%) is ranked lower than
70% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. TBIO: -58.81 )
Ranked among companies with meaningful Net-margin (%) only.
TBIO' s Net-margin (%) Range Over the Past 10 Years
Min: -58.05  Med: -21.04 Max: -2.06
Current: -58.81
-58.05
-2.06
ROE (%) -232.80
TBIO's ROE (%) is ranked lower than
95% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. TBIO: -232.80 )
Ranked among companies with meaningful ROE (%) only.
TBIO' s ROE (%) Range Over the Past 10 Years
Min: -167.63  Med: -44.24 Max: -3.63
Current: -232.8
-167.63
-3.63
ROA (%) -64.18
TBIO's ROA (%) is ranked lower than
80% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. TBIO: -64.18 )
Ranked among companies with meaningful ROA (%) only.
TBIO' s ROA (%) Range Over the Past 10 Years
Min: -47.75  Med: -18.86 Max: -2.7
Current: -64.18
-47.75
-2.7
ROC (Joel Greenblatt) (%) -368.83
TBIO's ROC (Joel Greenblatt) (%) is ranked lower than
75% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. TBIO: -368.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TBIO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -393.55  Med: -50.73 Max: -4.92
Current: -368.83
-393.55
-4.92
Revenue Growth (3Y)(%) -22.50
TBIO's Revenue Growth (3Y)(%) is ranked lower than
87% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. TBIO: -22.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TBIO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -23.5  Med: -11.90 Max: 9.9
Current: -22.5
-23.5
9.9
EBITDA Growth (3Y)(%) -4.70
TBIO's EBITDA Growth (3Y)(%) is ranked lower than
61% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. TBIO: -4.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TBIO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -54.7  Med: -1.80 Max: 71
Current: -4.7
-54.7
71
EPS Growth (3Y)(%) -8.50
TBIO's EPS Growth (3Y)(%) is ranked lower than
61% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. TBIO: -8.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TBIO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -58.4  Med: -8.50 Max: 178.9
Current: -8.5
-58.4
178.9
» TBIO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with TBIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.29
TBIO's P/B is ranked higher than
78% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.67 vs. TBIO: 1.29 )
Ranked among companies with meaningful P/B only.
TBIO' s P/B Range Over the Past 10 Years
Min: 0.97  Med: 2.23 Max: 704
Current: 1.29
0.97
704
P/S 0.23
TBIO's P/S is ranked higher than
96% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. TBIO: 0.23 )
Ranked among companies with meaningful P/S only.
TBIO' s P/S Range Over the Past 10 Years
Min: 0.17  Med: 1.21 Max: 3.51
Current: 0.23
0.17
3.51
Current Ratio 1.00
TBIO's Current Ratio is ranked lower than
90% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. TBIO: 1.00 )
Ranked among companies with meaningful Current Ratio only.
TBIO' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 2.48 Max: 18.01
Current: 1
0.96
18.01
Quick Ratio 1.00
TBIO's Quick Ratio is ranked lower than
84% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. TBIO: 1.00 )
Ranked among companies with meaningful Quick Ratio only.
TBIO' s Quick Ratio Range Over the Past 10 Years
Min: 0.67  Med: 1.77 Max: 17.35
Current: 1
0.67
17.35
Days Inventory 48.39
TBIO's Days Inventory is ranked higher than
67% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.26 vs. TBIO: 48.39 )
Ranked among companies with meaningful Days Inventory only.
TBIO' s Days Inventory Range Over the Past 10 Years
Min: 73.18  Med: 106.09 Max: 165.14
Current: 48.39
73.18
165.14
Days Sales Outstanding 102.33
TBIO's Days Sales Outstanding is ranked lower than
78% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. TBIO: 102.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
TBIO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 70.42  Med: 90.08 Max: 138.39
Current: 102.33
70.42
138.39
Days Payable 66.86
TBIO's Days Payable is ranked higher than
60% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. TBIO: 66.86 )
Ranked among companies with meaningful Days Payable only.
TBIO' s Days Payable Range Over the Past 10 Years
Min: 31.93  Med: 47.74 Max: 102.4
Current: 66.86
31.93
102.4

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.15
TBIO's Price/Median PS Value is ranked higher than
93% of the 226 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.97 vs. TBIO: 0.15 )
Ranked among companies with meaningful Price/Median PS Value only.
TBIO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.21  Med: 1.15 Max: 14.46
Current: 0.15
0.21
14.46
Price/Graham Number 0.31
TBIO's Price/Graham Number is ranked higher than
94% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. TBIO: 0.31 )
Ranked among companies with meaningful Price/Graham Number only.
TBIO' s Price/Graham Number Range Over the Past 10 Years
Min: 0.27  Med: 0.97 Max: 2.22
Current: 0.31
0.27
2.22
Earnings Yield (Greenblatt) (%) -118.42
TBIO's Earnings Yield (Greenblatt) (%) is ranked lower than
94% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. TBIO: -118.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TBIO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -116.91  Med: 24.90 Max: 40.5
Current: -118.42
-116.91
40.5

More Statistics

Revenue(Mil) $33
EPS $ -1.98
Short Percentage of Float4.62%
52-Week Range $0.61 - 3.75
Shares Outstanding(Mil)13.92

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:A, ROP, GRMN, HXGBY, TRMB » details
Traded in other countries:TGKN.Germany,
Transgenomic Inc was incorporated in Delaware on March 6, 1997. The Company is a biotechnology company advancing personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. Its operations are organized and reviewed by management along its product lines and presented in the following two complementary business segments: Laboratory Services and Genetic Assays and Platform. In Laboratory Services: its laboratories engaged in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. Its Patient Testing laboratories located in New Haven, Connecticut and Omaha, Nebraska are certified under the Clinical Laboratory Improvement Amendment ("CLIA") as high complexity laboratories and its Omaha facility is also accredited by the College of American Pathologists ("CAP"). Its laboratories employ genomic testing service technologies, including ICE COLD-PCR technology. ICE COLD-PCR is a proprietary platform technology that can be run in any laboratory with standard PCR technology and that enables detection of multiple unknown mutations from virtually any sample type including tissue biopsies, blood, cell-free DNA ("cfDNA") and circulating tumor cells ("CTCs") at levels greater than 1,000-fold higher than standard DNA sequencing techniques. In enetic Assays and Platforms: its proprietary product is the WAVE System, which has applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. It also distributes bioinstruments produced by other manufacturers ("OEM Equipment") through its sales and distribution network. The Company also distributes bioinstruments produced by other manufacturers ('OEM Equipment') through its sales and distribution network. Service contracts to maintain installed systems are sold and supported by its technical support personnel. The installed WAVE base and some OEM Equipment platforms generate a demand for consumables that are required for the continued operation of the bioinstruments. It develops, manufactures and sells these consumable products. In addition, it manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Competitors in these areas, among others, include Applied Biosystems, Qiagen, Roche, Sequenom and Illumina. Competition for some of its non-WAVE consumable products comes from numerous well-diversified life sciences reagent providers, including, among others, Invitrogen, Qiagen, Roche, Stratagene and Promega. The Company is subject to a variety of federal, state and municipal environmental and safety laws based on its use of hazardous materials in both manufacturing and research and development operations.
» More Articles for TBIO

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Transgenomic Highlights Unique Advantages of Multiplexed ICE COLD-PCR at Personalized Medicine World... Jan 26 2016
Transgenomic Highlights Unique Advantages of Multiplexed ICE COLD-PCR™ at Personalized Medicine... Jan 26 2016
SHAREHOLDER ALERT -The Law Offices of Vincent Wong Launch an Investigation into Transgenomic Inc. -... Jan 20 2016
TRANSGENOMIC INC Files SEC form 8-K, Change in Directors or Principal Officers Jan 20 2016
Transgenomic Launches New MX-ICP Panels for Liquid Biopsy Detection of RAS and PIK3CA Tumor... Jan 19 2016
Transgenomic Launches New MX-ICP Panels for Liquid Biopsy Detection of RAS and PIK3CA Tumor... Jan 19 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of... Jan 14 2016
Transgenomic Announces Conversion of Series A and B Preferred Securities and Extension of Loan... Jan 11 2016
Transgenomic Announces Private Placement Financing Jan 11 2016
TRANSGENOMIC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale... Jan 11 2016
Transgenomic Announces Conversion of Series A and B Preferred Securities and Extension of Loan... Jan 11 2016
Transgenomic Announces Private Placement Financing Jan 11 2016
Transgenomic Awarded NIH Grant to Augment Multiplexing Capabilities of ICE COLD-PCR Technology in... Dec 23 2015
Transgenomic Awarded NIH Grant to Augment Multiplexing Capabilities of ICE COLD-PCR™ Technology in... Dec 23 2015
Transgenomic Reports US Insurers Covering More Than 110 Million Lives Are Providing Reimbursement... Dec 21 2015
Transgenomic Finalizes Divestment Of Its Genetic Assays & Platforms Business Unit Dec 21 2015
Transgenomic Reports US Insurers Covering More Than 110 Million Lives Are Providing Reimbursement... Dec 09 2015
TRANSGENOMIC INC Financials Dec 08 2015
Transgenomic, Inc. Earnings Q3, 2015 Dec 02 2015
TRANSGENOMIC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of... Dec 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK